Baseline Therapeutics develops novel therapeutics for addiction indications, focusing initially on alcohol use disorder (AUD). The company is advancing a weekly GLP-1RA injectable, BT-001, which leverages existing safety data from metabolic trials. Phase 3 trials for AUD are scheduled to commence in 2026, with plans for subsequent indications.
Funding
Funding not disclosed
Founders
Product
Problem
Current addiction treatments often focus on symptom management rather than addressing the underlying neurobiological mechanisms. This approach can lead to suboptimal patient outcomes and a high rate of relapse.
Solution
Baseline Therapeutics is developing novel therapeutics designed to target the root biological drivers of addiction. Our platform utilizes a precision medicine approach, identifying and modulating specific neural pathways implicated in addictive behaviors. By intervening at the molecular and circuit level, we aim to create more effective and durable treatment options. This focus on fundamental biological processes differentiates our therapeutic strategy from existing interventions.
Target Audience
Our primary customers are pharmaceutical companies and research institutions seeking to license or co-develop novel therapeutics for addiction.
Features
- Proprietary platform for identifying novel therapeutic targets within addiction-related neural circuits.
- Development of small molecule and biologic drug candidates for addiction treatment.
- Focus on modulating neurotransmitter systems and intracellular signaling cascades.
- Preclinical and clinical development programs for substance use disorders.